Roivant Sciences Revenue and Competitors

Basel,

Location

$2.1B

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Roivant Sciences's estimated annual revenue is currently $57M per year.(i)
  • Roivant Sciences's estimated revenue per employee is $193,750
  • Roivant Sciences's total funding is $2.1B.
  • Roivant Sciences's current valuation is $7B. (May 2021)

Employee Data

  • Roivant Sciences has 294 Employees.(i)
  • Roivant Sciences grew their employee count by -7% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$81.4M37540%N/AN/A
#2
$16.9M10922%N/AN/A
#3
$156.1M120-70%$145MN/A
#4
$2.9M37-24%$150MN/A
#5
$15.3M99-49%$459.5MN/A
#6
$49.2M25415%$180.7MN/A
#7
$7M45-2%N/AN/A
#8
$256.3M8409%$168.5MN/A
#9
$4.5M29-6%N/AN/A
#10
$9.6M62-7%N/AN/A
Add Company

Roivant aims to improve health by rapidly delivering innovative medicines and technologies to patients. We do this by building Vants ? nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying technology. We have built 15 Vants to date and have raised over $3 billion to pursue our mission. The therapies in development across our family of companies target a wide range of diseases including uterine fibroids, endometriosis, prostate cancer, Parkinson?s disease, diabetes, sickle cell disease, and multiple rare and fatal pediatric conditions. We focus on disease areas where the magnitude of R&D investment from industry is disproportionately low relative to societal medical needs. In addition to our biopharmaceutical subsidiaries, we also build technology-focused Vants focused on improving the process of developing and commercializing medicines.

keywords:N/A

$2.1B

Total Funding

294

Number of Employees

$57M

Revenue (est)

-7%

Employee Growth %

$7B

Valuation

N/A

Accelerator

Roivant Sciences News

2022-04-17 - Roivant Sciences Ltd. (NASDAQ:ROIV) Expected to Announce ...

Roivant Sciences Ltd. (NASDAQ:ROIV) Expected to Announce Quarterly Sales of $15.41 Million. Posted by admin on Apr 16th, 2022.

2022-04-17 - -$0.25 Earnings Per Share Expected for Roivant Sciences Ltd ...

Wall Street brokerages predict that Roivant Sciences Ltd. (NASDAQ:ROIV – Get Rating) will report ($0.25) earnings per share (EPS) for the...

2022-03-22 - Sanford Burnham Prebys and Roivant Social Ventures ...

... 2022 (GLOBE NEWSWIRE) -- Roivant Social Ventures, a nonprofit philanthropic social impact organization launched by Roivant Sciences,...

2021-09-21 - Roivant Sciences Reports First Fiscal Quarter 2021 Financial Results and Provides Business Update

BASEL, Switzerland and LONDON and NEW YORK, Sept. 21, 2021 /PRNewswire/ -- Roivant Sciences Ltd. ("Roivant" or the "Company"), a next-generation biopharmaceutical company dedicated to improving the delivery of healthcare to patients, today reported its financial results for the fiscal quarter en ...

2021-06-09 - MONTES ARCHIMEDES ACQUISITION CORP. Montes Archimedes Acquisition : Roivant Provides Corporate Updates

NEW YORK and BASEL, Switzerland, June 9, 2021 /PRNewswire/ -- Roivant Sciences today announced that Datavant, the leader in helping healthcare organizations securely connect their data, and Ciox Health, the leader in clinical data exchange, have signed a definitive merger agreement. The combine ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$93M33832%N/A
#2
$109.2M39729%N/A
#3
$63.4M4094%N/A
#4
N/A42452%N/A
#5
N/A62321%N/A

Roivant Sciences Executives


NameTitle
Vivek RamaswamyFounder & CEO
Mayukh SukhatmePresident & Chief Investment Officer
Srini RamanathanChief Development Officer
Roger SidhuExecutive Vice President, Head of Research and Development and Chief Medical Officer
Srini RamanathanChief Development Officer
Matthew GlineChief Executive Officer
Benjamin PhamChief of Staff
Josephine FelipeExecutive Assistant to the Founder and CEO
Regina SavExecutive Assistant to the CFO
Paul DavisChief Communications Officer
Eric VenkerPresident and Chief Operating Officer
Matt HewmaisakChief Operating Officer, Roivant Platforms
Drew FromkinChief Executive Officer Proteovant, Vant Portfolio Operating Partner (Roivant Sciences)
Drew KramerChief Information Officer
Regina SavExecutive Business Partner, Office of the CEO
Rakhi KumarChief Accounting Officer
Richard PulikChief Financial Officer
Mayukh SukhatmePresident & Chief Investment Officer
Manish PondaVice President, Clinical Development
Roger SidhuExecutive Vice President, Head of Research and Development and Chief Medical Officer
Keith HaanVice President, Investments
Jason ImbriglioVP - Head of Platform Technology
Joe BishopVP of Finance
Sanjeev KothariSenior Vice President, CMC and Supply Chain
Jian-ping TangVice President, Head of Clinical Pharmacology
Nanxiang GeVP, Head of Biometrics and Data Management
Jon KluftVP Business Development
Benjamin ZimmerPresident, Roivant Health
Eric VenkerPresident and Chief Operating Officer
Matthew BlischakVice-President, Intellectual Property Counsel
Nik KhetarpalVP
Alex GasnerExecutive Vice President, Roivant Health
Eric ValeurVP Research, Head of Drug Discovery
Raj PunwaneyVice President, Clinical Development